Concepts (244)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Orthomyxoviridae Infections | 5 | 2019 | 1001 | 1.19 | Why? |
| Hepatitis B virus | 7 | 2018 | 882 | 0.93 | Why? |
| Hemagglutinins | 2 | 2019 | 143 | 0.90 | Why? |
| Hemagglutinin Glycoproteins, Influenza Virus | 4 | 2019 | 511 | 0.83 | Why? |
| Gene Deletion | 2 | 2017 | 430 | 0.74 | Why? |
| Ferrets | 5 | 2020 | 1201 | 0.71 | Why? |
| Carcinoma, Hepatocellular | 3 | 2018 | 1222 | 0.50 | Why? |
| Hepatitis A Vaccines | 3 | 2018 | 52 | 0.50 | Why? |
| Antibody Specificity | 1 | 2018 | 1328 | 0.49 | Why? |
| HIV Integrase Inhibitors | 3 | 2019 | 173 | 0.48 | Why? |
| Vaccines, Inactivated | 2 | 2019 | 1562 | 0.47 | Why? |
| Orthomyxoviridae | 2 | 2018 | 1168 | 0.47 | Why? |
| Liver Neoplasms | 2 | 2018 | 1666 | 0.37 | Why? |
| Hepatitis A | 3 | 2018 | 140 | 0.33 | Why? |
| Hepatitis B, Chronic | 3 | 2018 | 616 | 0.31 | Why? |
| Anti-Retroviral Agents | 4 | 2019 | 1099 | 0.31 | Why? |
| Influenza Vaccines | 2 | 2019 | 2941 | 0.30 | Why? |
| HIV Infections | 12 | 2019 | 11620 | 0.30 | Why? |
| Polymorphism, Single Nucleotide | 2 | 2017 | 3607 | 0.28 | Why? |
| Hepatitis B | 3 | 2018 | 888 | 0.28 | Why? |
| Influenza A Virus, H1N1 Subtype | 1 | 2019 | 2984 | 0.27 | Why? |
| HIV Seropositivity | 3 | 2019 | 320 | 0.23 | Why? |
| Hepatitis A Antibodies | 2 | 2018 | 18 | 0.23 | Why? |
| Hemagglutination Inhibition Tests | 2 | 2019 | 191 | 0.22 | Why? |
| Topotecan | 1 | 2021 | 62 | 0.22 | Why? |
| Topoisomerase I Inhibitors | 1 | 2021 | 63 | 0.22 | Why? |
| AIDS-Related Opportunistic Infections | 2 | 2017 | 260 | 0.22 | Why? |
| DNA Topoisomerases, Type I | 1 | 2021 | 86 | 0.21 | Why? |
| Hepatitis B e Antigens | 2 | 2018 | 99 | 0.21 | Why? |
| Homosexuality, Male | 3 | 2018 | 1158 | 0.20 | Why? |
| Enzyme-Linked Immunospot Assay | 2 | 2018 | 325 | 0.20 | Why? |
| Immunization, Secondary | 3 | 2018 | 1649 | 0.20 | Why? |
| Hepatitis B Surface Antigens | 2 | 2018 | 305 | 0.19 | Why? |
| Maintenance Chemotherapy | 1 | 2019 | 133 | 0.18 | Why? |
| Drug Evaluation, Preclinical | 2 | 2020 | 3347 | 0.18 | Why? |
| CpG Islands | 1 | 2019 | 230 | 0.18 | Why? |
| Benzoxazines | 1 | 2017 | 103 | 0.17 | Why? |
| Taiwan | 8 | 2018 | 2556 | 0.17 | Why? |
| Mycobacterium avium-intracellulare Infection | 1 | 2017 | 59 | 0.17 | Why? |
| DNA Repair | 1 | 2017 | 114 | 0.17 | Why? |
| Reverse Transcriptase Inhibitors | 1 | 2019 | 309 | 0.17 | Why? |
| Lab-On-A-Chip Devices | 1 | 2021 | 411 | 0.17 | Why? |
| Guanine | 1 | 2018 | 146 | 0.17 | Why? |
| Creatine Kinase | 1 | 2019 | 386 | 0.16 | Why? |
| Madin Darby Canine Kidney Cells | 1 | 2019 | 640 | 0.16 | Why? |
| Cross Protection | 1 | 2019 | 373 | 0.16 | Why? |
| Heterocyclic Compounds, 3-Ring | 1 | 2019 | 275 | 0.16 | Why? |
| Genome, Viral | 2 | 2017 | 13157 | 0.15 | Why? |
| Drug Resistance, Viral | 3 | 2017 | 1083 | 0.15 | Why? |
| Hepatitis B Vaccines | 1 | 2018 | 245 | 0.15 | Why? |
| Drug Substitution | 1 | 2019 | 385 | 0.15 | Why? |
| Lamivudine | 1 | 2016 | 210 | 0.15 | Why? |
| Antibodies, Viral | 7 | 2021 | 51949 | 0.15 | Why? |
| Endoplasmic Reticulum Stress | 1 | 2017 | 253 | 0.14 | Why? |
| Influenza A Virus, H7N9 Subtype | 1 | 2019 | 415 | 0.14 | Why? |
| Nucleosides | 1 | 2017 | 221 | 0.14 | Why? |
| Disease Models, Animal | 3 | 2021 | 10998 | 0.14 | Why? |
| Sofosbuvir | 1 | 2018 | 518 | 0.13 | Why? |
| Vaccines, Attenuated | 1 | 2019 | 952 | 0.13 | Why? |
| Antiretroviral Therapy, Highly Active | 1 | 2019 | 952 | 0.13 | Why? |
| Tenofovir | 1 | 2016 | 449 | 0.13 | Why? |
| RNA Viruses | 1 | 2020 | 824 | 0.12 | Why? |
| Endemic Diseases | 1 | 2016 | 480 | 0.12 | Why? |
| Neoplasm Proteins | 1 | 2017 | 501 | 0.12 | Why? |
| Cell Line | 4 | 2021 | 12040 | 0.11 | Why? |
| Animals | 13 | 2021 | 78931 | 0.11 | Why? |
| Dogs | 1 | 2019 | 2529 | 0.11 | Why? |
| Plasma | 1 | 2021 | 1809 | 0.11 | Why? |
| Hepacivirus | 2 | 2018 | 1509 | 0.11 | Why? |
| Immunization | 1 | 2019 | 2019 | 0.10 | Why? |
| Adjuvants, Immunologic | 1 | 2019 | 1709 | 0.10 | Why? |
| Liver Cirrhosis | 2 | 2018 | 1810 | 0.10 | Why? |
| Interferons | 2 | 2020 | 2885 | 0.10 | Why? |
| Dysentery, Amebic | 1 | 2008 | 6 | 0.10 | Why? |
| Vaccination | 4 | 2019 | 19050 | 0.10 | Why? |
| High-Throughput Nucleotide Sequencing | 2 | 2018 | 3633 | 0.10 | Why? |
| Antiviral Agents | 5 | 2021 | 41703 | 0.09 | Why? |
| Hepatitis C, Chronic | 1 | 2018 | 973 | 0.09 | Why? |
| Recombinant Proteins | 1 | 2019 | 3786 | 0.09 | Why? |
| Pre-Exposure Prophylaxis | 1 | 2017 | 1138 | 0.09 | Why? |
| Pneumococcal Vaccines | 1 | 2014 | 571 | 0.09 | Why? |
| Interferon-gamma | 1 | 2017 | 2711 | 0.08 | Why? |
| Cross Reactions | 1 | 2019 | 4374 | 0.08 | Why? |
| CD4 Lymphocyte Count | 3 | 2018 | 1517 | 0.08 | Why? |
| Mutation | 2 | 2018 | 12376 | 0.08 | Why? |
| Peptide Fragments | 1 | 2017 | 2075 | 0.08 | Why? |
| Communicable Diseases, Emerging | 1 | 2021 | 2523 | 0.08 | Why? |
| Neutralization Tests | 1 | 2020 | 6698 | 0.08 | Why? |
| Sustained Virologic Response | 2 | 2019 | 378 | 0.08 | Why? |
| Liver | 1 | 2021 | 4007 | 0.08 | Why? |
| Influenza A virus | 1 | 2018 | 2234 | 0.08 | Why? |
| Mice | 6 | 2021 | 21357 | 0.08 | Why? |
| Autoantibodies | 1 | 2017 | 2094 | 0.08 | Why? |
| Immunoglobulin G | 4 | 2018 | 21571 | 0.08 | Why? |
| Immunoglobulin A | 1 | 2018 | 3567 | 0.08 | Why? |
| Mesocricetus | 2 | 2021 | 1847 | 0.07 | Why? |
| Immunity, Cellular | 1 | 2018 | 3614 | 0.07 | Why? |
| Vero Cells | 4 | 2021 | 14117 | 0.07 | Why? |
| Host-Pathogen Interactions | 3 | 2021 | 11041 | 0.07 | Why? |
| Male | 21 | 2021 | 367725 | 0.06 | Why? |
| Humans | 33 | 2021 | 930598 | 0.06 | Why? |
| Protease Inhibitors | 1 | 2019 | 3630 | 0.06 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 7868 | 0.06 | Why? |
| Lung | 2 | 2021 | 31049 | 0.06 | Why? |
| Multivariate Analysis | 3 | 2017 | 5440 | 0.06 | Why? |
| 3T3 Cells | 1 | 2021 | 152 | 0.06 | Why? |
| Pulmonary Embolism | 1 | 2021 | 4775 | 0.06 | Why? |
| Drug Repositioning | 1 | 2020 | 5683 | 0.06 | Why? |
| HIV-1 | 1 | 2016 | 3365 | 0.06 | Why? |
| Adult | 18 | 2021 | 244371 | 0.05 | Why? |
| Transduction, Genetic | 1 | 2021 | 273 | 0.05 | Why? |
| Dependovirus | 1 | 2021 | 272 | 0.05 | Why? |
| Hepatitis C | 1 | 2011 | 1514 | 0.05 | Why? |
| THP-1 Cells | 1 | 2021 | 374 | 0.05 | Why? |
| Green Fluorescent Proteins | 1 | 2021 | 450 | 0.05 | Why? |
| Mice, Inbred BALB C | 2 | 2021 | 5814 | 0.05 | Why? |
| Autopsy | 2 | 2021 | 3495 | 0.05 | Why? |
| Hydrazones | 1 | 2020 | 216 | 0.05 | Why? |
| Polysorbates | 1 | 2019 | 125 | 0.05 | Why? |
| Retrospective Studies | 7 | 2019 | 105322 | 0.05 | Why? |
| Patient Acceptance of Health Care | 1 | 2017 | 5002 | 0.05 | Why? |
| Squalene | 1 | 2019 | 196 | 0.05 | Why? |
| Alum Compounds | 1 | 2019 | 210 | 0.05 | Why? |
| Cytochrome P-450 CYP2B6 | 1 | 2017 | 12 | 0.05 | Why? |
| Morpholines | 1 | 2020 | 351 | 0.05 | Why? |
| Alkynes | 1 | 2017 | 98 | 0.04 | Why? |
| Triazines | 1 | 2020 | 246 | 0.04 | Why? |
| Hepatitis A Virus, Human | 1 | 2017 | 12 | 0.04 | Why? |
| Drug Combinations | 2 | 2019 | 3852 | 0.04 | Why? |
| Guinea Pigs | 1 | 2018 | 420 | 0.04 | Why? |
| Oxazines | 1 | 2019 | 279 | 0.04 | Why? |
| Virus Internalization | 3 | 2021 | 7921 | 0.04 | Why? |
| Primates | 1 | 2020 | 584 | 0.04 | Why? |
| Hepatitis A virus | 1 | 2018 | 68 | 0.04 | Why? |
| Sexuality | 1 | 2017 | 85 | 0.04 | Why? |
| Female | 16 | 2021 | 380317 | 0.04 | Why? |
| CHO Cells | 1 | 2019 | 831 | 0.04 | Why? |
| Drug Synergism | 1 | 2020 | 833 | 0.04 | Why? |
| Antibodies, Neutralizing | 3 | 2019 | 25288 | 0.04 | Why? |
| Metabolome | 1 | 2021 | 624 | 0.04 | Why? |
| Cricetulus | 1 | 2019 | 936 | 0.04 | Why? |
| Lymphocyte Depletion | 1 | 2018 | 293 | 0.04 | Why? |
| Piperazines | 1 | 2019 | 445 | 0.04 | Why? |
| Carcinogenesis | 1 | 2018 | 236 | 0.04 | Why? |
| Raltegravir Potassium | 1 | 2016 | 132 | 0.04 | Why? |
| Dose-Response Relationship, Immunologic | 1 | 2017 | 593 | 0.04 | Why? |
| Cyclopropanes | 1 | 2017 | 332 | 0.04 | Why? |
| Metabolomics | 1 | 2021 | 921 | 0.04 | Why? |
| Induced Pluripotent Stem Cells | 1 | 2020 | 584 | 0.04 | Why? |
| Superior Sagittal Sinus | 1 | 2014 | 2 | 0.04 | Why? |
| Seroepidemiologic Studies | 3 | 2018 | 10017 | 0.04 | Why? |
| Health Knowledge, Attitudes, Practice | 1 | 2017 | 8811 | 0.03 | Why? |
| Patient Acuity | 1 | 2021 | 1755 | 0.03 | Why? |
| Transcription, Genetic | 1 | 2020 | 1326 | 0.03 | Why? |
| Chemokines | 1 | 2020 | 1095 | 0.03 | Why? |
| Heptavalent Pneumococcal Conjugate Vaccine | 1 | 2014 | 64 | 0.03 | Why? |
| Mice, Transgenic | 1 | 2021 | 2739 | 0.03 | Why? |
| Longitudinal Studies | 2 | 2021 | 9893 | 0.03 | Why? |
| Cysteine Proteinase Inhibitors | 1 | 2020 | 675 | 0.03 | Why? |
| Immunohistochemistry | 1 | 2021 | 2275 | 0.03 | Why? |
| Pyridones | 1 | 2019 | 738 | 0.03 | Why? |
| Cricetinae | 1 | 2021 | 3344 | 0.03 | Why? |
| Vaccines, Subunit | 1 | 2019 | 1088 | 0.03 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.03 | Why? |
| Genotype | 2 | 2017 | 4697 | 0.03 | Why? |
| Syphilis | 1 | 2017 | 318 | 0.03 | Why? |
| Case-Control Studies | 3 | 2018 | 17671 | 0.03 | Why? |
| Viral Load | 3 | 2021 | 15850 | 0.03 | Why? |
| Sexual Partners | 1 | 2017 | 612 | 0.03 | Why? |
| Logistic Models | 2 | 2017 | 9089 | 0.03 | Why? |
| Pyrimidines | 1 | 2020 | 1557 | 0.03 | Why? |
| Dyslipidemias | 1 | 2019 | 791 | 0.03 | Why? |
| Alveolar Epithelial Cells | 1 | 2020 | 1445 | 0.03 | Why? |
| Small Molecule Libraries | 1 | 2020 | 1060 | 0.03 | Why? |
| Counseling | 1 | 2017 | 747 | 0.03 | Why? |
| Ribavirin | 1 | 2018 | 1182 | 0.03 | Why? |
| Treatment Outcome | 4 | 2019 | 51732 | 0.03 | Why? |
| Dose-Response Relationship, Drug | 1 | 2020 | 3776 | 0.03 | Why? |
| Mice, Inbred C57BL | 1 | 2021 | 5542 | 0.03 | Why? |
| Sequence Homology | 1 | 2011 | 448 | 0.03 | Why? |
| Middle Aged | 9 | 2021 | 270681 | 0.03 | Why? |
| Antibodies, Bacterial | 1 | 2014 | 510 | 0.02 | Why? |
| Inflammation Mediators | 1 | 2021 | 2654 | 0.02 | Why? |
| Kinetics | 1 | 2018 | 3238 | 0.02 | Why? |
| Flow Cytometry | 1 | 2018 | 2393 | 0.02 | Why? |
| Entamoeba histolytica | 1 | 2008 | 22 | 0.02 | Why? |
| Virus Replication | 2 | 2020 | 14331 | 0.02 | Why? |
| Cells, Cultured | 1 | 2020 | 5835 | 0.02 | Why? |
| Pneumonia, Viral | 4 | 2020 | 243684 | 0.02 | Why? |
| Coronavirus Infections | 4 | 2020 | 253789 | 0.02 | Why? |
| Sexual Behavior | 1 | 2017 | 1322 | 0.02 | Why? |
| Antigens, Protozoan | 1 | 2008 | 121 | 0.02 | Why? |
| Young Adult | 5 | 2018 | 93724 | 0.02 | Why? |
| Leukocytes, Mononuclear | 1 | 2018 | 2115 | 0.02 | Why? |
| Hemagglutination Tests | 1 | 2008 | 124 | 0.02 | Why? |
| Inflammation | 2 | 2021 | 13255 | 0.02 | Why? |
| Blood Coagulation | 1 | 2021 | 2768 | 0.02 | Why? |
| Seroconversion | 1 | 2018 | 2515 | 0.02 | Why? |
| Gene Expression Regulation | 1 | 2020 | 4020 | 0.02 | Why? |
| Cytokines | 2 | 2021 | 15010 | 0.02 | Why? |
| New York City | 1 | 2021 | 7432 | 0.02 | Why? |
| Cause of Death | 1 | 2021 | 4823 | 0.02 | Why? |
| Follow-Up Studies | 2 | 2017 | 17020 | 0.02 | Why? |
| Molecular Sequence Data | 1 | 2011 | 3198 | 0.02 | Why? |
| Biomarkers | 2 | 2021 | 23361 | 0.02 | Why? |
| Phylogeny | 2 | 2016 | 13341 | 0.02 | Why? |
| ROC Curve | 1 | 2017 | 6024 | 0.02 | Why? |
| Machine Learning | 1 | 2021 | 4395 | 0.02 | Why? |
| Drug Therapy, Combination | 1 | 2018 | 7268 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2017 | 6543 | 0.02 | Why? |
| Acute Disease | 1 | 2017 | 6029 | 0.02 | Why? |
| Time Factors | 2 | 2018 | 31397 | 0.02 | Why? |
| Reproducibility of Results | 1 | 2020 | 11304 | 0.02 | Why? |
| Serologic Tests | 1 | 2018 | 4359 | 0.02 | Why? |
| Costs and Cost Analysis | 1 | 2008 | 694 | 0.02 | Why? |
| Cluster Analysis | 1 | 2011 | 3001 | 0.02 | Why? |
| Genetic Variation | 1 | 2017 | 3919 | 0.02 | Why? |
| Models, Biological | 1 | 2020 | 4907 | 0.02 | Why? |
| Sequence Analysis, DNA | 1 | 2011 | 2830 | 0.02 | Why? |
| Adenosine Monophosphate | 1 | 2020 | 5652 | 0.02 | Why? |
| Alanine | 1 | 2020 | 5687 | 0.02 | Why? |
| Incidence | 2 | 2017 | 25622 | 0.02 | Why? |
| Aged, 80 and over | 3 | 2021 | 88759 | 0.01 | Why? |
| Cohort Studies | 2 | 2019 | 36005 | 0.01 | Why? |
| Disease Progression | 1 | 2021 | 13580 | 0.01 | Why? |
| Immunity, Innate | 1 | 2020 | 6570 | 0.01 | Why? |
| RNA, Viral | 2 | 2021 | 32276 | 0.01 | Why? |
| Antigens, Viral | 1 | 2018 | 6298 | 0.01 | Why? |
| Pandemics | 4 | 2020 | 389249 | 0.01 | Why? |
| Prospective Studies | 2 | 2017 | 43301 | 0.01 | Why? |
| Disease Outbreaks | 2 | 2018 | 27595 | 0.01 | Why? |
| Viral Vaccines | 1 | 2020 | 7560 | 0.01 | Why? |
| Cost-Benefit Analysis | 1 | 2008 | 2259 | 0.01 | Why? |
| Prognosis | 1 | 2021 | 32490 | 0.01 | Why? |
| Coinfection | 1 | 2016 | 6820 | 0.01 | Why? |
| Risk Factors | 2 | 2019 | 71621 | 0.01 | Why? |
| Aged | 3 | 2021 | 215776 | 0.01 | Why? |
| Prevalence | 1 | 2016 | 25773 | 0.01 | Why? |
| Viral Nonstructural Proteins | 1 | 2011 | 4810 | 0.01 | Why? |
| Severity of Illness Index | 1 | 2021 | 48226 | 0.01 | Why? |
| Influenza, Human | 1 | 2018 | 10779 | 0.01 | Why? |
| Adolescent | 2 | 2017 | 86841 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2017 | 43792 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2017 | 53120 | 0.01 | Why? |